E. Kavalerchik

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.

G. Noronha, Annelie Abrahamsson, J. Durocher, 2008, Cancer cell.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Michael L. Wang, D. Siegel, R. Orlowski, 2013, Blood.

Investigation of the ATP binding site of Escherichia coli aminoimidazole ribonucleotide synthetase using affinity labeling and site-directed mutagenesis.

J. Stubbe, S. Ealick, S. Oh, 1999, Biochemistry.

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2015, Leukemia & lymphoma.

Chronic myeloid leukemia stem cells.

C. Jamieson, D. Goff, E. Kavalerchik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

436PDPreliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors

H. Beltran, F. Kaye, A. Mansfield, 2017 .

Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC).

J. McKenney, C. Magi-Galluzzi, B. Rini, 2017 .

Chronic myeloid leukemia stem cells.

C. Jamieson, D. Goff, E. Kavalerchik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.